On (cell surface), in (intracellular), and out (extracellular/systemic): Are we targeting all that matters in cancer immunotherapy?

References

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer J Clin. 2024; 74(1):12-49. doi: 10.3322/caac.21820

[2] Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020; 52(1):17-35. doi: 10.1016/j.immuni.2019.12.011

[3] Sharma P, Siddiqui BA, Anandhan S, et al. The next decade of immune checkpoint therapy. Cancer Discov. 2021; 11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680

[4] Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020; 382(7):610-621. doi: 10.1056/NEJMoa1914510

[5] Garcia-Mouronte E, Berna-Rico E, de Nicolas-Ruanes B, Azcarraga-Llobet C, Alonso-Martinez de Salinas L, Bea-Ardebol S. Imiquimod as local immunotherapy in the management of premalignant cutaneous conditions and skin cancer. Int J Mol Sci. 2023; 24(13):10835. doi: 10.3390/ijms241310835

[6] Li H, Zhou Q, Cao N, et al. Nanobodies and their derivatives: pioneering the future of cancer immunotherapy. Cell Commun Signal. 2025; 23(1). doi: 10.1186/s12964-025-02270-4

[7] Kalluri R. The biology and function of exosomes in cancer. J Clin Investig. 2016; 126(4):1208-1215. doi: 10.1172/JCI81135